BMT Diagnostics (58925)

Rapid Diagnostics Test- based on PATENT- NO STEP

The company was founded in 2004 and has been active in developing, manufacturing and marketing rapid diagnostic tests (RDT) in Israel and abroad base on PATENTS-NO STEP (StrepA-Covid 19 Ag (sample from throat)-Influeanza A+B), etc.

Focused initially on introducing rapid diagnostic tests to pharmacies and health maintenance organizations (HMO) for self and professional testing, the company has led the adoption of Strep A RDT as a firstline screening tool by physicians and patients. This has created a new market opportunity, opening the door to additional tests that bridge the patient-physician chasm.

Over the last two decades there has been a significant market shift in extending medical testing from hospitals’ laboratories to Point-of-Care (POC) physician office/clinic settings and to private homes (e.g. pregnancy tests and glucose tests). However, most RDT (excluding glucose tests) are still predominantly performed in hospitals and by POC professionals, since standard tests and kits have yet to overcome the regulatory challenges associated with developing a user-friendly product that will widely appeal to health-conscious consumers.

The company has pioneered a first of its kind, simple-to-use, integrated device for Strep A-COVID19 &Influenza A+B  testing under its Lab-On-Time Trade Mark. It is in the process of developing additional swab-based tests based on its Lab-On-Time™ platform. It has one international patent application covering its core swab-based integrated sampling and testing device platform.

After receiving validation and establishing a credible foothold in the European market, the company will begin to expand into the USA and other territories.



Distributers of rapid diagnostics tests.